Redx is a clinical-stage biotechnology company focused on the discovery and development of novel, small molecule, highly targeted therapeutics for the treatment of cancer and fibrotic disease.
RXC004 is a clinical stage, highly potent and selective, orally active once-daily Porcupine inhibitor being developed as a targeted therapy for Wnt-ligand driven cancer.
Drug discovery with
a strong track record
Exceptional capabilities in medicinal chemistry and translational science are the foundation of Redx. The Company has built an attractive portfolio of assets and has a strong track record of drug discovery. Redx’s drug discovery engine has delivered four molecules which have gone into the clinic and delivered a number of major partnering transactions. Our lead product RXC004 is in Phase 2 in patients with advanced malignancies. The Company’s selective ROCK2 inhibitor, RXC007, is currently in Phase 1.
ASCO 2022 – A multi-arm, Phase 2, open-label study to assess the efficacy of RXC004 as monotherapy and in combination with Nivolumab, in patients with Ring Finger Protein 43 (RNF43) or R-Spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable Colorectal Cancer, following standard treatment